logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trialsā€¦ read more

Healthcare

Biotechnology

13 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$6.34

Price

-2.61%

-$0.17

$6.51

Previous Close

$6.46

Open

Premium

52w Discount
Market Cap

$341.620m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$35.101m

-30.6%

1y CAGR

-32.8%

3y CAGR

-24.8%

5y CAGR
EPS

-$0.71

-18.3%

1y CAGR

-11.2%

3y CAGR

-3.4%

5y CAGR
Book Value

$47.235m

$53.080m

Assets

$5.845m

Liabilities

$212k

Debt
Debt to Assets

0.4%

-

Debt to EBITDA
Free Cash Flow

-$31.086m

-25.9%

1y CAGR

-35.2%

3y CAGR

-25.0%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.